Tocris Bioscience

From Wikipedia, the free encyclopedia

This article or section is written like an advertisement.
Please help rewrite this article from a neutral point of view.
Mark blatant advertising which would require a fundamental rewrite in order to become encyclopedic for speedy deletion, using {{db-spam}}. (June 2008)

This article may not meet the notability guidelines for companies and organizations. If you are familiar with the subject matter, please expand or rewrite the article to establish its notability. The best way to address this concern is to reference published, third-party sources about the subject. If notability cannot be established, the article is more likely to be considered for redirection, merge or ultimately deletion, per Wikipedia:Guide to deletion.
This article has been tagged since June 2008.

This article or section needs sources or references that appear in reliable, third-party publications.
Primary sources and sources affiliated with the subject of the article are generally not sufficient for a Wikipedia article. Please include more appropriate citations from reliable sources, or discuss the issue on the talk page.
This article has been tagged since June 2008.

Tocris Bioscience is a supplier of chemicals, peptides and antibodies as biological tools. These are useful as GPCR agonists and antagonists, nuclear receptor ligands, ion channel modulators and signal transduction inhibitors for pre-clinical research.

[edit] Company History

Tocris Bioscience is the trading name for the companies in the Tocris Cookson Group consisting of Tocris Cookson Ltd. and its wholly owned US subsidiary Tocris Cookson Inc. Tocris Cookson Ltd. is privately held and headquartered in Bristol, UK. Tocris Cookson Inc. is located in St. Louis, MO, USA. There are approximately 60 employees in the Group worldwide, operating out of three sites in the UK and one in the US.
Tocris Cookson Ltd was incorporated in the UK in July 1994 as the result of a merger between Tocris Neuramin Ltd of Bristol, UK and Cookson Chemicals Ltd of Southampton, UK.
Tocris Neuramin was founded in 1982 by Professor Jeff Watkins of the Pharmacology Department in the University of Bristol, UK. Watkins’ research interests focused on glutamate receptors and their involvement in the synaptic transmission processes of the mammalian central nervous system. Tocris Neuramin was founded to make standard research tools and novel probes in this field easily available to researchers, at least partly in response to the number of requests for samples Watkins was receiving at the time.^[1]
Cookson Chemicals was formed in 1985 by Richard Cookson, Professor of Organic Chemistry at the University of Southampton, UK. Cookson Chemicals provided custom synthesis services as well as a range of neurochemicals to the pharmaceutical and allied industries.
In 2002 Tocris Cookson was awarded The Queen's Awards for Enterprise in the International Trade category.
In January 2007 Tocris Bioscience announced the successful completion of a $40 million MBO. Watkins and Cookson no longer have any involvement in the company.

Today, Tocris Bioscience has customers in virtually all of the worlds major pharmaceutical companies, universities and research institutes, with a catalogue of over 2000 products which is sent to more than 50,000 researchers worldwide annually.